Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.

Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, Muller RU, Straka E, Su L, Burki EA, Crowell RE, Patel R, Kulkarni T, Homer R, Zelterman D, Kidd KK, Zhu Y, Christiani DC, Belinsky SA, Slack FJ, Weidhaas JB.

Cancer Res. 2008 Oct 15;68(20):8535-40. doi: 10.1158/0008-5472.CAN-08-2129.

2.

Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis.

Langevin SM, Christensen BC.

Cancer Med. 2014 Oct;3(5):1385-95. doi: 10.1002/cam4.279. Epub 2014 Jun 2. Review.

3.

Differential expression of biomarkers in men and women.

Planchard D, Loriot Y, Goubar A, Commo F, Soria JC.

Semin Oncol. 2009 Dec;36(6):553-65. doi: 10.1053/j.seminoncol.2009.09.004. Review.

PMID:
19995647
4.

MicroRNA-mediated regulation of KRAS in cancer.

Kim M, Slack FJ.

J Hematol Oncol. 2014 Nov 30;7:84. doi: 10.1186/s13045-014-0084-2. Review.

5.

Association of rs712 polymorphism in Kras gene 3'-luntranslated region and cancer risk: a meta-analysis.

Zhao WH, Qu XF, Xing ZG, Zhao LQ, Qin L, Lv C.

J BUON. 2015 Jan-Feb;20(1):309-16. Review.

PMID:
25778332
6.

MicroRNA binding site polymorphisms as biomarkers in cancer management and research.

Cipollini M, Landi S, Gemignani F.

Pharmgenomics Pers Med. 2014 Jul 23;7:173-91. doi: 10.2147/PGPM.S61693. eCollection 2014. Review.

Supplemental Content

Support Center